• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    7/12/23 1:37:39 PM ET
    $ADIL
    $AVRO
    $BDRX
    $BKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Healthcare Triangle (NASDAQ:HCTI) stock rose 109.2% to $6.82 during Wednesday's regular session. Healthcare Triangle's stock is trading at a volume of 26.4 million shares as of 13:37 EST. This is 69329.6% of its average full-day volume over the last 100 days. The company's market cap stands at $29.1 million.
    • Recursion Pharmaceuticals (NASDAQ:RXRX) stock moved upwards by 83.61% to $12.45. The current volume of 60.4 million shares is 2852.6% of Recursion Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $2.3 billion.
    • Petros Pharma (NASDAQ:PTPI) shares moved upwards by 81.04% to $3.44. As of 13:37 EST, this security is trading at a volume of 14.2 million shares, making up 545.2% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million.
    • Avrobio (NASDAQ:AVRO) stock rose 41.82% to $1.39. Trading volume for this security as of 13:37 EST is 24.0 million, which is 1028.1% of its average full-day volume over the last 100 days. The company's market cap stands at $61.2 million.
    • InspireMD (NASDAQ:NSPR) shares increased by 29.56% to $2.98. The current volume of 691.1K shares is 669.5% of InspireMD's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $63.1 million.
    • Freeline Therapeutics (NASDAQ:FRLN) shares rose 25.98% to $4.67. As of 13:37 EST, this security is trading at a volume of 13.7 million shares, making up 9034.5% of its average full-day volume over the last 100 days. The company's market cap stands at $20.3 million.

    Losers

    • Silk Road Medical (NASDAQ:SILK) shares declined by 29.5% to $23.01 during Wednesday's regular session. Trading volume for this security as of 13:37 EST is 7.3 million, which is 1247.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $891.1 million.
    • CytoMed Therapeutics (NASDAQ:GDTC) stock declined by 27.84% to $4.07. Trading volume for CytoMed Therapeutics's stock is 739.5K as of 13:37 EST. This is 134.8% of its average full-day volume over the last 100 days. The company's market cap stands at $46.9 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock fell 25.87% to $0.29. Adial Pharmaceuticals's stock is trading at a volume of 5.6 million shares as of 13:37 EST. This is 256.0% of its average full-day volume over the last 100 days. The company's market cap stands at $8.5 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock decreased by 21.01% to $4.76. Trading volume for this security as of 13:37 EST is 609.6K, which is 385.9% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 million.
    • T2 Biosystems (NASDAQ:TTOO) shares fell 17.88% to $0.12. The current volume of 80.4 million shares is 197.0% of T2 Biosystems's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $3.0 million.
    • Brookdale Senior Living (NYSE:BKD) stock fell 12.53% to $3.77. The current volume of 1.4 million shares is 82.9% of Brookdale Senior Living's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $709.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $AVRO
    $BDRX
    $BKD

    CompanyDatePrice TargetRatingAnalyst
    InspireMD Inc.
    $NSPR
    2/2/2026$6.00Buy
    Maxim Group
    Brookdale Senior Living Inc.
    $BKD
    1/6/2026$13.00Underperform → Buy
    BofA Securities
    Recursion Pharmaceuticals Inc.
    $RXRX
    12/17/2025$11.00Neutral → Overweight
    Analyst
    Brookdale Senior Living Inc.
    $BKD
    11/10/2025$14.00Equal Weight → Overweight
    Barclays
    Recursion Pharmaceuticals Inc.
    $RXRX
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    Brookdale Senior Living Inc.
    $BKD
    4/1/2025$7.00Equal Weight
    Barclays
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Brookdale Senior Living Inc.
    $BKD
    10/16/2024$8.00Buy
    Jefferies
    More analyst ratings

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on InspireMD with a new price target

    Maxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00

    2/2/26 7:53:56 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Brookdale Senior Living upgraded by BofA Securities with a new price target

    BofA Securities upgraded Brookdale Senior Living from Underperform to Buy and set a new price target of $13.00

    1/6/26 8:25:08 AM ET
    $BKD
    Hospital/Nursing Management
    Health Care

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dar Zavain

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:26 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Li Dean Y

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:19 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Gibson Christopher

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    3/25/26 4:36:02 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion to Participate in Upcoming Investor Conferences

    Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational med

    4/7/26 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

    April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s

    4/2/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brookdale Announces Successful Refinancing Transaction; Extends 2027 Non-Recourse Mortgage Debt Maturity

    BRENTWOOD, Tenn., April 2, 2026 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE:BKD) ("Brookdale" or "the Company") announced today the Company completed a successful refinancing transaction from KeyBank's real estate business through its Freddie Mac loan origination program, effectively extending a significant portion of the Company's 2027 debt maturities. On March 31, 2026, the Company obtained an aggregate $185 million of debt on seven communities and repaid $191 million of outstanding mortgage debt secured by 11 communities previously scheduled to mature in March 2027. Th

    4/2/26 7:00:00 AM ET
    $BKD
    Hospital/Nursing Management
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Stuka Paul bought $4,905 worth of shares (2,710 units at $1.81), increasing direct ownership by 0.70% to 391,628 units (SEC Form 4)

    4/A - InspireMD, Inc. (0001433607) (Issuer)

    2/23/26 4:05:19 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $9,182 worth of shares (5,073 units at $1.81), increasing direct ownership by 1% to 391,628 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/11/25 4:05:09 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $9,436 worth of shares (5,073 units at $1.86), increasing direct ownership by 1% to 388,918 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/8/25 4:05:12 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Brookdale Senior Living Inc.

    SCHEDULE 13G - Brookdale Senior Living Inc. (0001332349) (Subject)

    4/6/26 1:12:33 PM ET
    $BKD
    Hospital/Nursing Management
    Health Care

    InspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - InspireMD, Inc. (0001433607) (Filer)

    4/3/26 4:01:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by InspireMD Inc.

    424B5 - InspireMD, Inc. (0001433607) (Filer)

    4/3/26 3:53:53 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international demand for CGuard.Supported over 500 cumulative carotid procedures utilizing CGuard Prime across leading hospitals and integrated delivery networks since launch.Co

    3/18/26 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the star

    3/9/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AVRO
    $BDRX
    $BKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care